Active Not Recruiting INTERVENTIONAL NCT04303780

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Sponsor: Amgen

Conditions KRAS p, G12c Mutated /Advanced Metastatic NSCLC

Interventions AMG 510 Docetaxel

Updated 31 times since 2020 Last updated: Apr 16, 2026 Started: Jun 4, 2020 Primary completion: Aug 2, 2022 Completion: Jun 24, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on KRAS p, G12c Mutated /Advanced Metastatic NSCLC, this trial is ongoing. The trial is conducted by Amgen and has accumulated 31 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

31 versions recorded

May 4, 2026 — Present [daily]

Active Not Recruiting

Phase: PHASE3 → None
Dec 2025 — May 2026 [monthly]

Active Not Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Oct 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 26 earlier versions

Aug 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Mar 2025 — Aug 2025 [monthly]

Active Not Recruiting PHASE3
Nov 2024 — Mar 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3
Nov 2023 — Apr 2024 [monthly]

Active Not Recruiting PHASE3
Jun 2023 — Nov 2023 [monthly]

Active Not Recruiting PHASE3
Dec 2022 — Jun 2023 [monthly]

Active Not Recruiting PHASE3
Sep 2022 — Dec 2022 [monthly]

Active Not Recruiting PHASE3
Jan 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE3
Dec 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE3
Oct 2021 — Dec 2021 [monthly]

Active Not Recruiting PHASE3
Sep 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE3
May 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Apr 2021 — May 2021 [monthly]

Recruiting PHASE3
Feb 2021 — Apr 2021 [monthly]

Recruiting PHASE3
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Nov 2020 — Dec 2020 [monthly]

Recruiting PHASE3
Oct 2020 — Nov 2020 [monthly]

Recruiting PHASE3
Sep 2020 — Oct 2020 [monthly]

Recruiting PHASE3
Aug 2020 — Sep 2020 [monthly]

Recruiting PHASE3
Jul 2020 — Aug 2020 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
May 2020 — Jul 2020 [monthly]

Not Yet Recruiting PHASE3
Apr 2020 — May 2020 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation

Contact Information

Sponsor contact:

Amgen

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A CoruÃ±a, Spain , Akashi-shi, Japan , Albany, United States , Albany, United States , Amsterdam, Netherlands , Anaheim, United States , Ann Arbor, United States , Athens, Greece , Athens, Greece , Athens, Greece and 264 more locations